23 January 2007
Munich, Germany and Barcelona, Spain – Affectis Pharmaceuticals AG, a biopharmaceutical company developing novel drugs for the treatment of depression and schizophrenia, announced today that it has in-licensed a novel, selective Cox-2 inhibitor from Palau Pharma, the R&D subsidiary of Grupo Uriach. Affectis will develop the compound, named Cimicoxib, as a treatment for depression and schizophrenia. The company expects to start a Phase II trial in depression with Cimicoxib this year.
| File | File size |
|---|---|
 07-01 Affectis Inlicensing Palau engl.pdf | 30 Kb |
24 October 2006
Munich, Germany – Affectis Pharmaceuticals AG, a biopharmaceutical company developing novel drugs against depression and schizophrenia, has closed a € 12 million series C financing round. The round was led by Aescap Venture, a new investor in Affectis. All existing investors participated in the round. In addition, Affectis has strengthened its management team and Advisory Board. Dr Michael Bös, previously Director of Chemistry at Boehringer Ingelheim (Canada) Ltd., has joined Affectis as Vice President, Research and Development. Dr Domenico (Dinko) Valerio, Co-Founder and General Partner of Aescap Venture, will join the Supervisory Board of Affectis. Affectis will use the proceeds of the financing round to advance its product candidates.
Affectis has selected lead candidates targeting the P2X7 pathway, one of which will be taken into clinical development soon. P2X7 is an ion channel involved in neuroprotection, the modulation of inflammatory processes, and in neurotransmission in the hippocampus region of the brain. Studies published by Affectis earlier this year demonstrated a strong association between a genetic variant of the receptor gene and the onset of depression and bipolar disorders.
| File | File size |
|---|---|
| 24.10.06 Affectis Aescap E.pdf | 25 Kb |
24 July 2006
Munich, Germany – Affectis Pharmaceuticals AG, a biopharmaceutical company developing novel drugs against depression and schizophrenia, announced today that it has identified a genetic variation associated with major depressive disorder. (1) As the variation may have consequences for the functioning of a receptor protein in the brain, it constitutes a promising target for the development of novel anti-depressants. In a previous paper published in May this year Affectis already had demonstrated that the variant is strongly associated with bipolar affective disorders. (2) According to WHO figures, in 2002 worldwide 154 million people suffered from unipolar disorder, while about 28 million suffered from bipolar affective disorders.
| File | File size |
|---|---|
| 2006-07 Affectis paper 2 E final.pdf | 29 Kb |
Copyright © 2010 Affectis Pharmaceuticals AG. All Rights Reserved.
